A Parental Request for an Unproven Treatment for a Rare Pediatric Cancer: Sound Reasons for Not Going Off-Label

We present the case of a three-year-old in remission from ependymoma whose parents requested off-label metformin in the hope that it could reduce her chance of recurrence. A prominent specialist who was developing a clinical trial studying metformin as an adjunctive treatment for children with relap...

Description complète

Enregistré dans:  
Détails bibliographiques
Auteurs: Hedlin, Margot (Auteur) ; Voigt, Louis (Auteur)
Type de support: Électronique Article
Langue:Anglais
Vérifier la disponibilité: HBZ Gateway
Interlibrary Loan:Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany)
Publié: 2026
Dans: The Hastings Center report
Année: 2026, Volume: 56, Numéro: 2, Pages: 13-15
Sujets non-standardisés:B parental decision-making
B pediatric oncology
B Bioethics
B clinical ethics consultation
B off-label prescribing
Accès en ligne: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000naa a22000002c 4500
001 1965621279
003 DE-627
005 20260318055505.0
007 cr uuu---uuuuu
008 260318s2026 xx |||||o 00| ||eng c
024 7 |a 10.1002/hast.5025  |2 doi 
035 |a (DE-627)1965621279 
035 |a (DE-599)KXP1965621279 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Hedlin, Margot  |e VerfasserIn  |4 aut 
245 1 2 |a A Parental Request for an Unproven Treatment for a Rare Pediatric Cancer: Sound Reasons for Not Going Off-Label 
264 1 |c 2026 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a We present the case of a three-year-old in remission from ependymoma whose parents requested off-label metformin in the hope that it could reduce her chance of recurrence. A prominent specialist who was developing a clinical trial studying metformin as an adjunctive treatment for children with relapsed ependymoma had recommended metformin for the patient based on theoretical chance of benefit. The child's primary neuro-oncologist sought an ethics consult, as he did not believe that prescribing metformin off-label to this patient was ethical. We argue that he should not prescribe the medication. Current data do not support its use, and it carries nontrivial risks. Moreover, prescribing unproven treatments outside of a trial risks giving families false hope, undermining clinical research, and creating pressure on physicians to offer unproven interventions. Social media amplifies these requests, shaping parental decision-making and potentially spreading unvalidated practices. Physicians may respond compassionately while declining to provide interventions outside standard care. This case highlights the ethical boundaries of off-label prescribing in pediatric oncology. 
650 4 |a Bioethics 
650 4 |a parental decision-making 
650 4 |a off-label prescribing 
650 4 |a clinical ethics consultation 
650 4 |a pediatric oncology 
700 1 |a Voigt, Louis  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a Hastings Center  |t The Hastings Center report  |d Malden, Mass. : Wiley, 1971  |g 56(2026), 2, Seite 13-15  |h Online-Ressource  |w (DE-627)341346551  |w (DE-600)2067369-3  |w (DE-576)258761822  |x 1552-146X  |7 nnas 
773 1 8 |g volume:56  |g year:2026  |g number:2  |g pages:13-15 
856 4 0 |u https://doi.org/10.1002/hast.5025  |x Resolving-System  |z lizenzpflichtig  |3 Volltext  |7 1 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.5025  |x Verlag  |z lizenzpflichtig  |3 Volltext  |7 1 
912 |a NOMM 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 493774089X 
LOK |0 003 DE-627 
LOK |0 004 1965621279 
LOK |0 005 20260318055505 
LOK |0 008 260318||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2026-03-17#AEA3879CB2D611C7F4A804BFBD78E212DB64FA3D 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a zota  |a tiep 
LOK |0 939   |a 2026-03-18  |b l01 
ORI |a TA-MARC-ixtheoa001.raw